3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Lymphoma
89
Lymphoma, Non-Hodgkin
86
Precursor Cell Lymphoblastic Leukemia-Lymphoma
81
Leukemia, Lymphocytic, Chronic, B-Cell
65
Lymphoma, Large B-Cell, Diffuse
54
Lymphoma, Follicular
50
Burkitt Lymphoma
40
Hodgkin Disease
39
Recurrence
37
Multiple Myeloma
33
Leukemia, Myeloid, Acute
32
Leukemia
32
Lymphoma, Mantle-Cell
31
Lymphoma, B-Cell
31
Neoplasms
23
Myelodysplastic Syndromes
22
Hematologic Neoplasms
21
Lymphoma, B-Cell, Marginal Zone
17
Waldenstrom Macroglobulinemia
16
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
14
Leukemia, B-Cell
14
Sarcoma
13
Lymphoma, T-Cell
11
Lymphoma, Large-Cell, Anaplastic
11
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
10
Lymphoma, T-Cell, Peripheral
10
Glioma
10
Osteosarcoma
9
Neuroblastoma
9
Mycosis Fungoides
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colitis, Ulcerative
×
Lymphoid
×
30 days
×
Clear all
NCT02808780
2026-06-05
OPAL
Janssen Biotech, Inc.
Active not recruiting
535 enrolled